Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study

Alzheimers Dement (Amst). 2015 Oct 9;1(4):403-11. doi: 10.1016/j.dadm.2015.09.002. eCollection 2015 Dec.


Introduction: Ascertainment of the pattern and temporal change of biomarkers in preclinical (asymptomatic) sporadic Alzheimer's disease (AD) will increase knowledge about early pathogenesis and facilitate interventional therapeutic trials.

Methods: In this prospective longitudinal study, repeated cerebrospinal fluid (CSF) collections and cognitive evaluations were performed in cognitively healthy elderly individuals during a 9-year period.

Results: Low CSF β-amyloid (Aβ)42 levels predicted subsequent development of clinical AD 9 years later. Noteworthy, one-third of individuals with pathologically low baseline Aβ42 levels remained cognitively intact during follow-up. No further decrease in Aβ42 was seen in those with low levels already at baseline.

Discussion: CSF Aβ42 predicts sporadic AD at least 9 years before dementia onset and has plateaued already at this time. However, many individuals can harbor brain amyloid accumulation over a decade without signs of cognitive deterioration, which could implicate how CSF biomarkers are used to identify preclinical AD in future interventional therapeutic trials.

Keywords: Alzheimer's disease; Cerebrospinal fluid; Cognitive aging; Cohort studies; Dementia; Tau protein; β-Amyloid1–42.